The interplay between aging and cellular senescence reveals insights into chronic inflammation and potential strategies for enhancing healthspan and longevity.

IDT and Elegen partner to launch an early access program offering long, clonal gene synthesis and high-complexity genes up to 15 kb.

In this interview, Technology Networks talked to Dr. Stacy Lindborg, president, chief executive officer and board member at IMUNON, Inc., who shares how its PlaCCine® platform could reshape vaccine ...

Toxicity related to the systematic delivery of IL-12, a well-known and widely researched anti-tumor cytokine, has limited its ...

With a grant award from the American Mosquito Control Association Research Fund, Utah State University ecologist Norah ...

On March 23, direct-to-consumer genetic testing company 23andMe announced it had filed for bankruptcy. The move came after ...

The therapy, EPI-321, is intended to treat cases of facioscapulohumeral muscular dystrophy, a genetic neuromuscular disorder.

Chennai’s high pollution, fast-paced life, and disease risks make health insurance essential to cover medical expenses.

LUXTURNA has significant market potential due to the high unmet need for effective treatments in rare genetic conditions. With its FDA approval for specific mutations in the RPE65 gene, it offers ...

DelveInsight's "LUXTURNA Market Size, Forecast, and Market Insight Report" highlights the details around LUXTURNA, a one-time ...

Below, check out the roundup of California Healthline’s coverage. For today's national health news, read KFF Health News’ Morning Briefing.